Policy Analysis: Investment, Life Sciences
Published:

UCL spin out sold to Amgen in $1 billion deal

University College London cancer vaccines spin-out BioVex has been bought by US biotech company Amgen in deal worth up to $1 billion.

BioVex, a cancer vaccines specialist spun out of University College London (UCL) is being acquired by US biotechnology giant Amgen in an all-cash deal worth up to $1 billion. Amgen is paying $425 million upfront, with a further $575 million to come on reaching some clinical and regulatory milestones.

The acquisition is a welcome return for the venture capital (VC) investors who have supported the company through six private rounds of investment, since it was formed in...



Related subjects: Cancer

The 2015 Science|Business Annual Summit
The Science|Business Annual Summit brings together leaders from research, industry and policy to debate current and future trends needed to unleash Europe’s technological potential.
Barcelona - 20 November 2015
The future of manufacturing: Industry 4.0 (Date to be confirmed)
A Science|Business public conference
Brussels - 01 October 2015
The Bioeconomy Challenge: Producing more from less
A Science|Business high-level roundtable
Brussels - 29 September 2015
Views of 2030: Transport, manufacturing, education and health
In October 2014, members of the Science|Business Network of universities and companies met in Berlin to compare notes about the future of four key sectors in Europe. This is what they see coming.